Podcast: International Cannabis And Psychedelics Co. Is Working 'Hand In Hand' With FDA To Forge New Therapy Frontiers

Welcome to the inaugural episode of the Benzinga Psychedelics Podcast. In this exciting kickoff, we're joined by Joel Latham, experienced biotech industry leader and CEO of Incannex Healthcare IXHL.

Dive into our engaging conversation as we explore Incannex's strategic expansion into broader markets, its pioneering role in Australia's psychedelic-assisted therapies and its management of a substantial drug portfolio.

What Is Incannex And What Does It Do?

Incannex is a clinical-stage pharmaceutical company developing medicinal cannabinoid drugs and psychedelic medicine therapies. The company has been gathering all necessary permits and is about to open what would be the first dedicated psychedelic-assisted therapy clinic in Melbourne, Australia, where the national regulatory authority has authorized treatment with MDMA and psilocybin for PTSD and treatment-resistant depression.

See Also: Australian Psychiatrists Provide First Psychedelic-Assisted Medical Treatments In 50 Years

The biotech company has recently redomiciled to the U.S. "for a greater opportunity for us to grow and develop, given the two sectors that we're in," delisting from the Australian Stock Exchange (ASX) for a simplified corporate structure.

Its strategy focuses on scientifically validating novel drugs and therapies, "working hand in hand with the FDA to achieve authorization and registration for the indications targeted."

With 28 assets currently under development, all reportedly de-risked with positive clinical and preclinical data, Latham says the company's "deep" IP portfolio in the cannabinoid and psychedelic research centers puts Incannex "in a really strong position commercially," providing many opportunities for the company to provide favorable outcomes for shareholders while also making "a significant difference in the lives of millions of patients suffering from the indications that we’re targeting."

Nonetheless, Incannex's main focus to date is set on three assets: two cannabinoid-based products, and one psychedelic-associated compound in development.

Listen to the full episode on Spotify or find it on any podcasting platform, searching for “Benzinga Interviews.”

Photo courtesy of Incannex Healthcare, edited by Benzinga